There are currently 54 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Advanced Cancer participants are Texas, California, Florida and New York.
A Study in Patients With Advanced Cancers
NCT05320588
Recruiting
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/15/2022
Locations: NEXT Oncology Austin, Austin, Texas +2 locations
Conditions: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Register for Updates
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
NCT03922204
Recruiting
This is a Phase 1, open label, non-randomised, dose-escalation single agent study with expansion cohorts for dose confirmation/safety and preliminary efficacy of MCLA-145 in advanced or metastatic malignancies
Gender:
All
Ages:
18 years and above
Trial Updated:
05/25/2022
Locations: Moores Cancer Centre, La Jolla, California +9 locations
Conditions: Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
Register for Updates
Biomarkers For Immune Checkpoint Inhibitors
NCT04204434
Recruiting
This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of immunotherapy that stimulates a patients immune system to fight their cancer. Immune checkpoint inhibitors are standard, FDA approved treatment for certain types of cancers such as melanoma, lung cancer, kidney cancer and bladder cancer. The laboratories of Dr. Jack Elias and Dr. Chun Geun Lee at Brown University are studying how immune checkpoint inhibitors work.Kintai Therapeutics is a biotech company in Camb... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/19/2022
Locations: Rhode Island Hospital, Providence, Rhode Island +1 locations
Conditions: Advanced Cancer, Neoplasms
Register for Updates
PEN-866 in Patients With Advanced Solid Malignancies
NCT03221400
Recruiting
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: Highlands Oncology Group, Springdale, Arkansas +15 locations
Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Register for Updates
Care Transition Intervention for Hospitalized Patients With Advanced Cancer
NCT05142345
Recruiting
This study is examining whether a care transition intervention, CONTINUUM (CONTINUity of care Under Management by video visits), consisting of a supportive care-focused video visit with an oncology nurse practitioner (NP) within three business days of hospital discharge, may improve post-discharge transitions of care for recently hospitalized patients with advanced cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/10/2022
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Cancer, Follow-Up Care, Consultation, Remote, Advanced Cancer
Register for Updates
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
NCT04859777
Recruiting
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors. The study will be conducted in 3 parts: Part A: MPT-0118 dose-escalation Part B: MPT-0118 dose-escalation in combination with pembrolizumab Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
09/15/2021
Locations: St. John's Cancer Center, Santa Monica, California +4 locations
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
Register for Updates